Hugel (145020) Stock Outlook 2026: Letybo's US Entry and the Botulinum Toxin Big 3 Challenge
Hugel (KRX 145020) 2026 stock outlook. A deep qualitative analysis of its botulinum toxin (Botulax/Letybo) and HA filler (The Chaeum) business, the US FDA approval and American aesthetics market entry, China and Europe expansion, the GS Group consortium acquisition, the toxin strain-origin litigation risk, and how a Korean challenger competes against the global Big 3.
Hugel 145020 Letybo